Starget Pharma Overview
Starget Pharma is focused on creating products for the diagnosis and targeted treatment of cancer through the use of targeted radiotherapy. The company develops molecules that serve as a vector for selectively transferring imaging materials and treatments directly to tumor tissue.
Cumulative Funding Raised Over Time ($)
$10.0MDec 2019
$15.1MOct 2024
Latest News
growth-positive
Starget Pharma Receives $5.1M Investment From Cancer Focus Fund
Starget Pharma, a biotechnology company based in Tel Aviv, has secured a $5.1 million investment from Cancer Focus Fund. The funding will be used to conduct a Phase 1b clinical trial of its lead theranostic, DOTA-PTR-58. Starget Pharma specializes in developing precision peptide radioligand therapies using its proprietary Backbone Dynamics peptide platform. The companys lead program targets the SSTR-3 somatostatin receptor, which is overexpressed in tumor cells. Initial data has shown promising safety and tumor uptake, and the Phase 1b trial is set to begin in early 2025 at MD Anderson and other centers. The company also has a pipeline targeting various metastatic cancers.
Investment
growth-positive
אילקס מדיקל משקיעה 10 מיליון ד' בסטארט-אפ לאבחון ולטיפול בסרטן
אילקס מדיקל (Elkx Medical) has announced an investment of $10 million in Starget Pharma, a company specializing in the diagnosis and treatment of cancer through targeted radioactive radiation. Starget Pharma is developing molecules that serve as a carrier for the selective transfer of imaging materials and drugs to the tumor tissue. This is a significant move for Elkx Medical, which has not invested in external companies developing new products in recent years. The investment is part of Elkx Medicals strategy to invest in the medical field over the next one to two years.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $15.1M |
| Last funding | $5.1M |
| Stage | Seed |
| Rounds | 2 |
| Investors | 2 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | stargetpharma.com/ |
Locations
Ramat Hasharon, Israel
Photos & Videos
No files yet
Starget Pharma Business
Business models
B2B
Product stage
R&D
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryTest Diagnostics & ScreeningTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsMoleculesTags (5)
cancer-therapypeptidespharmaceuticalsdiagnosticsbiotechnologyStarget Pharma Financials
$15.1M
Total funding
Undisclosed
Capital raised
$5.1M
Last funding
Seed
Funding stage
2
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$10.0MDec 2019
$15.1MOct 2024
Private Equity Funding
Undisclosed Round
Oct 2024
$5.1M
Cancer Focus Fund (Lead)
Undisclosed Round
Dec 2019
$10M
Undisclosed Investor(s)
Starget Pharma Lifecycle
Cumulative Funding Raised Over Time
$10.0MDec 2019
$15.1MOct 2024
All Events
Undisclosed Round
Oct 2024
$5.1M
Cancer Focus Fund (Lead)
Undisclosed Round
Dec 2019
$10M
Undisclosed Investor(s)
Starget Pharma News
2 articles
growth-positive
Starget Pharma Receives $5.1M Investment From Cancer Focus Fund
Starget Pharma, a biotechnology company based in Tel Aviv, has secured a $5.1 million investment from Cancer Focus Fund. The funding will be used to conduct a Phase 1b clinical trial of its lead theranostic, DOTA-PTR-58. Starget Pharma specializes in developing precision peptide radioligand therapies using its proprietary Backbone Dynamics peptide platform. The companys lead program targets the SSTR-3 somatostatin receptor, which is overexpressed in tumor cells. Initial data has shown promising safety and tumor uptake, and the Phase 1b trial is set to begin in early 2025 at MD Anderson and other centers. The company also has a pipeline targeting various metastatic cancers.
Investment
growth-positive
אילקס מדיקל משקיעה 10 מיליון ד' בסטארט-אפ לאבחון ולטיפול בסרטן
אילקס מדיקל (Elkx Medical) has announced an investment of $10 million in Starget Pharma, a company specializing in the diagnosis and treatment of cancer through targeted radioactive radiation. Starget Pharma is developing molecules that serve as a carrier for the selective transfer of imaging materials and drugs to the tumor tissue. This is a significant move for Elkx Medical, which has not invested in external companies developing new products in recent years. The investment is part of Elkx Medicals strategy to invest in the medical field over the next one to two years.
Investment
Starget Pharma Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 18 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
Starget Pharma Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | video or image, markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 516057411 |
| Crunchbase | starget-pharma-ltd |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-05-10T00:00:00.000Z |
| Created | 2021-11-17T00:00:00.000Z |